Drugs that contain Bimatoprost

1. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(1 year, 2 months from now)

US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(2 years from now)

US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(3 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(3 years from now)

US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(4 years from now)

US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2029

(6 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

2. List of Latisse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8038988 ALLERGAN Method of enhancing hair growth
Aug, 2023

(6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8986715 ALLERGAN Method of enhancing hair growth
Jan, 2023

(23 days ago)

US9226931 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(23 days ago)

US8632760 ALLERGAN Method of enhancing hair growth
Jan, 2023

(23 days ago)

US8263054 ALLERGAN Method of enhancing hair growth
Jan, 2023

(23 days ago)

US8758733 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(23 days ago)

US9216183 ALLERGAN Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Jan, 2023

(23 days ago)

US8101161 ALLERGAN Method of enhancing hair growth
May, 2024

(1 year, 3 months from now)

Market Authorisation Date: 24 December, 2008

Treatment: Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; Treatment of hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness

Dosage: SOLUTION/DROPS;TOPICAL

How can I launch a generic of LATISSE before it's patent expiration?
More Information on Dosage

3. List of Lumigan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(2 years from now)

Market Authorisation Date: 31 August, 2010

Treatment: A method of lowering intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; Method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIGAN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic